This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Thousand Oaks, CA-based Amgen is one of the biggest biotech companies in the world, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation, bone health and nephrology markets. The company used advances in cellular and molecular biology to develop two of the biotech industry’s earliest and most successful drugs, Epogen (anemia) and Neupogen (white blood cell stimulant). Amgen successfully launched two next-generation products, Aranesp and Neulasta. Meanwhile, the acquisition of Immunex Corporation gave Amgen access to the multi-blockbuster drug, Enbrel. However, all these older drugs are facing declining sales due to biosimilar or branded competition, which is being somewhat offset by its newer blockbuster drugs like Prolia/Xgeva
Key Predictions for Q3 Earnings Reports of ABBV, MRK
by Zacks Equity Research
The third quarter reporting cycle is witnessing accelerating revenues and positive revisions trend for Q4. Let's see if some of the other leading players AbbVie and Merck follow suit.
Biogen (BIIB) Tops Q3 Earnings & Sales, Spinraza Sales Up
by Zacks Equity Research
Biogen (BIIB) exceeds both earnings and sales estimates in the third quarter of 2017. The company's newest drug Spinraza's continual strong performance drives its revenue.
Novartis (NVS) Q3 Earnings & Sales Top on New Drugs Strength
by Zacks Equity Research
Novartis AG (NVS) third-quarter results topped estimates driven by strong performance of Cosentyx and Entresto.
What's in the Cards for Amgen (AMGN) this Earnings Season?
by Zacks Equity Research
While Amgen's (AMGN) growth drugs like Prolia & Xgeva might continue to do well, biosimilar competition and slowdown in sales of mature products can put pressure on sales growth.
Teva Submits BLA to FDA for Migraine Candidate Fremanezumab
by Zacks Equity Research
Teva Pharma (TEVA) submits BLA seeking approval for its pipeline candidate, Fremanezumab, as a preventive treatment for migraine in the United States.
What's in the Cards for Novartis (NVS) This Earnings Season?
by Zacks Equity Research
Swiss pharmaceutical company Novartis AG (NVS) is scheduled to report third-quarter 2017 results on Oct 24.
ImmunoGen to Push Leukemia Candidate into Phase I Trial
by Zacks Equity Research
ImmunoGen (IMGN) plans to move its leukemia candidate, IMGN632, into phase I study before the year ends. Also, the FDA has completed the safety review of its IND application for IMGN632.
Zacks Industry Outlook Highlights: Gilead, Teva, Pfizer and Amgen
by Zacks Equity Research
Zacks Industry Outlook Highlights: Gilead, Teva, Pfizer and Amgen
Pharma Industry Outlook - October 2017
by Arpita Dutt
New product sales ramping up, R&D success and innovation, strong results, a higher number of FDA approvals and continued strong performance from key products are some of the factors that could contribute to a sustained recovery in the sector.
Mylan Gets Complete Response Letter For Biosimilar Neulasta
by Zacks Equity Research
Mylan (MYL) suffered a setback following the FDA's CRL for the company's BLA for MYL-1401H, a proposed biosimilar of Neulasta.
Amgen Label Expansion Application for Prolia Accepted by FDA
by Zacks Equity Research
Amgen (AMGN) announced that the FDA has accepted its regulatory application in the U.S. seeking label expansion for Prolia for treating patients with glucocorticoid-induced osteoporosis (GIOP).
Forget Teva (TEVA), Buy These 5 Drug Stocks Instead
by Arpita Dutt
With another challenge cropping up for Teva (TEVA) in the form of earlier-than-expected generic competition for the 40 mg dose of Copaxone, here is a look at 5 drug stocks that look better-positioned.
Cancer Space Last Week Update: Pipeline Expansion in Focus
by Zacks Equity Research
Last week, a few companies in the cancer segment entered deals for expanding their portfolio. Another key development was a ruling in favor of a major cancer drug by the U.S. patent office.
Regeneron and Sanofi Get Favorable Ruling Against Amgen
by Zacks Equity Research
Regeneron Pharmaceuticals(REGN) and partner Sanofi, Inc. (SNY) receives a favorable ruling from the Court of Appeals for the Federal Circuit relating to Praluent.
AbbVie (ABBV) Stock Up Almost 17% in One Month: Here's Why
by Zacks Equity Research
AbbVie's (ABBV) shares have gained an impressive 16.7% in the past month supported by a series of positive news for the company in the past few weeks.
Amgen Enters Into an Immuno-Oncology Partnership With CytomX
by Zacks Equity Research
Amgen (AMGN) has entered into a strategic immuno-oncology collaboration with CytomX to jointly develop a T-cell engaging bispecific probody.
3 Top-Ranked Big Biotech Stocks to Buy Now
by Zacks Equity Research
With biotech stocks on a tear, here we have picked three of the biggest biotech companies which look well poised for growth and can be added to one's portfolio
Radius (RDUS) Enrols First Patient in Breast Cancer Study
by Zacks Equity Research
Radius Health, Inc. (RDUS) announced that the first patient has been enroled in the phase I study on breast cancer candidate RAD140.
How Will Trump's Proposed Tax Reform Impact Drug Companies?
by Zacks Equity Research
Donald Trump has proposed new tax reforms for individuals and corporates. Let's see how the reforms, if passed, will impact pharma companies.
Ligand's Captisol Deals Set to Drive Growth in the Long Run
by Zacks Equity Research
Ligand's (LGND) Captisol formulation technology platform allows it to partner with several leading drug companies, thus helping it earn milestones and royalty payments in turn.
Allergan (AGN) Pipeline & New Drugs to Counter Generic Woes
by Zacks Equity Research
Allergan's key drugs like Botox/Linzess and new drugs are supporting sales. However, Allergan faces generic threat for Namenda franchise and patent challenges for some other branded drugs.
Sanofi Rides on Genzyme & Vaccines Unit, Diabetes Sales Weak
by Zacks Equity Research
Sanofi's (SNY) Genzyme and Vaccines units are driving sales. Sales from the Diabetes franchise however continue to drop.
Biotech Stock Roundup: Amgen Reiterates 2017 Outlook, Intercept Hit by Ocaliva Safety Issues
by Arpita Dutt
Key highlights this week include Amgen's (AMGN) update regarding Hurricane Maria and safety issues concerning Intercept's Ocaliva.
Merck's Keytruda Gets FDA Nod for Advanced Gastric Cancer
by Zacks Equity Research
Merck's (MRK) Keytruda received FDA approval for advanced gastric cancer, making it the tenth new indication approved for Keytruda.
4 Sell-Ranked Biotech Stocks with Falling Estimates to Avoid
by Zacks Equity Research
Though the biotech industry is doing well, it's a good idea to avoid a few stocks in the industry which will not prove to be prudent additions to your portfolio.